The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

Clinical Pharmacokinetics

Volumn 55, Issue 4, 2016, Pages 409-418

  Echizen, Hirotoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; AMOXICILLIN; ASPARTATE AMINOTRANSFERASE; CLARITHROMYCIN; GASTRIN; LANSOPRAZOLE; VONOPRAZAN; 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE; CYTOCHROME P450 2C19; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; SULFONAMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONSTIPATION; DIARRHEA; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; FOOD INTAKE; GASTRIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NEUROENDOCRINE TUMOR; PEPTIC ULCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLUX ESOPHAGITIS; SECONDARY PREVENTION; SIDE EFFECT; STOMACH PARIETAL CELL; STOMACH PH; URINARY EXCRETION; VOLUME OF DISTRIBUTION; ANIMAL; BIOAVAILABILITY; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP2C19; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 84961156522     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0326-7     Document Type: Article

References (32)

1. Soll AH, Achord JL, Bozymski G, Brooks S, Lanza F, Lyon D, Meyer G, Reinus J, Schuster M, Achord J, Ofman J, Glassman P, Laine L, Tytgat G, Walsh JH, Graham DY, Peterson WL. Medical treatment of peptic ulcer disease: practice guidelines. JAMA. 1996;275:622–9.
2. Axon A. Helicobacter pylori and public health. Helicobacter. 2014;19(Suppl 1):68–73.
3. Fock KM, Ang TL, Bee LC, Lee EJD. Proton pump inhibitors. Clin Pharmacokinet. 2008;47:1–6.
4. Katz PO, Hatlebakk JG, Gstell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000;14:709–14.
5. Shaw MJ, Crawley JA. Improving health-related quality of life in gastro-oesophageal reflux disease. Drugs. 2003;63:2307–16.
6. Cheng HC, Sheu BS. Intravenous proton pump inhibitors in the management for peptic ulcer bleeding: clinical benefits and limits. World J Gastrointest Endosc. 2011;3:49–56.
7. Furuta T, Sugimoto M, Shirai N. Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19. Mol Diagn Ther. 2012;16:223–34.
8. Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs. 2005;14:411–21.
9. ®), a novel acid pump antagonist, for duodenal ulcer: results of a double-blind, randomized, parallel, multi-center phase III clinical trial. Korean J Gastrointest Endosc. 2005;31(1):17–24.
10. ®) for gastric ulcer. Korean J Gastrointest Endosc. 2007;34(6):312–9.
11. Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, Yoneyama T, Ashida K, Ogama Y, Warrington S. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636–48.
12. Umegaki E, Iwakiri K, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg once-daily) compared to lansoprazole (15 mg once-daily) in a 24-week maintenance treatment for healed erosive esophagitis. Gastroenterology. 2014;146:738.
13. Mizokami Y, Ashida K, Soen S, et al. TAK-438 versus lansoprazole 15 mg for secondary prevention of peptic ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy: results of a phase 3 trial. Gastroenterology. 2014;146:739.
14. Kawai T, Ashida K, Mizokami Y, et al. TAK-438 versus lansoprazole 15 mg for secondary prevention of peptic ulcers associated with low-dose aspirin therapy: results of a phase 3 trial. Gastroenterology. 2014;146:739.
15. Murakami K, Sakurai Y, Shiino M, et al. A phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy with TAK-438, amoxicillin, and metronidazole as second line eradication of H. pylori. Gastroenterology. 2014;146:740.
16. Iwakiri K, Umegaki E, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (20 mg once-daily) compared to lansoprazole (30 mg once-daily) in patients with erosive esophagitis. Gastroenterology. 2014;146:741.
17. Sakurai Y, Mori Y, Okamoto H, et al. A crossover study to evaluate the acid-inhibitory effect of a newly developed potassium-competitive acid blocker, vonoprazan, compared with esomeprazole or rabeprazole. Gastroenterology. 2015;148:S-620.
18. Mizokami Y, Oda K, Saito K, et al. A phase 3, lansoprazole-controlled, long-term extension study to evaluate the safety and efficacy of vonoprazan (10 mg or 20 mg) for prevention of recurrent peptic ulcers during long-term therapy with non-steroidal anti-inflammatory drug (NSAID). Gastroenterology. 2015;148:S-88–S-89.
19. Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75:439–43.
20. Drug approval review for vonoprazan fumarate (in Japanese), the Pharmaceuticals and Medical Devices Agency of Japan. 2014. https://www.pmda.go.jp/. Accessed 28 May 2015.
21. ® tablets 10 mg and 20 mg) ver. 3, (in Japanese). Takeda Pharmaceutical Company Limited. 2015. http://www.takeda.co.jp/. Accessed 28 May 2015.
22. ® tablets 10 mg and 20 mg ver. 2 (in Japanese). 2015. http://www.takeda.co.jp/. Accessed 28 May 2015.
23. Arikawa Y, Nishida H, Kurasawa O, Hasuoka A, Hirase K, Inatomi N, Hori Y, Matsukawa J, Imanishi A, Kondo M, Tarui N, Hamada T, Takagi T, Takeuchi T, Kajino M. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55:4446–56.
24. Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, Sachs G. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412–20.
25. Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, Hirase K, Kajino M, Inatomi N. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231–8.
26. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry, drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 26 Aug 2015.
27. European Medicine Agency (EMA), Committee for Human Medicinal Products (CHMP). Guideline on the investigation of drug interactions. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf. Accessed 26 Aug 2015.
28. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509–33.
29. Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145–51.
30. Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion-tolerance and rebound. Aliment Pharmacol Ther. 1997;11:1013–8.
31. Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Ann Intern Med. 1994;121:232–3.
32. Klinkenberg-Knol EC, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661–9.